Sirolimus in pediatric transplant recipients

Area of Science:

• Pediatric transplantation
• Immunosuppression
• Pharmacology

Background:

• Calcineurin inhibitors (CI) present unique, lifelong risks in pediatric organ transplant recipients, including sepsis, renal failure, and post-transplant lymphoproliferative disorder (PTLD).
• Pivoting from CI is crucial for improving long-term outcomes in this vulnerable population.

Purpose of the Study:

• To explore the efficacy and safety of sirolimus (SRL) as a novel antiproliferative immunosuppressant in pediatric organ transplant recipients.
• To evaluate SRL for rescue therapy, primary immunosuppression, and tacrolimus (TAC) toxicity management.

Main Methods:

• Retrospective analysis of sirolimus (SRL) use in over 85 pediatric patients receiving abdominal and thoracic organ transplants.
• Investigated SRL for primary immunosuppression, as a rescue agent, and for tacrolimus (TAC) elimination in cases of toxicity.
• Assessed SRL in steroid-sparing regimens for liver transplantation.

Main Results:

• Initial success with SRL in 50 pediatric patients.
• Exploration of SRL for tacrolimus (TAC) toxicity and in steroid-sparing liver transplant protocols.
• Over 85 children treated with SRL, with early results indicating potential.

Conclusions:

• Sirolimus (SRL) demonstrates potential as a primary immunosuppressive agent in pediatric organ transplantation under specific protocols.
• SRL may offer a viable alternative to calcineurin inhibitors (CI), mitigating unique pediatric side effect profiles.
• Further research and defined protocols are warranted to optimize SRL use in this population.